Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03328494

Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies

Advanced Nonhaematologic Malignancies Clinical Trial

Official title:
A Phase 1/1b Study of Paclitaxel in Combination With BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients With Advanced Nonhaematologic Malignancies

Clinical Trial Summary

This study will be conducted to assess the safety and tolerability of BOS172722 when administered as monotherapy and in combination with paclitaxel in participants with advanced nonhaematologic malignancies and also to establish the maximum tolerated dose and recommended Phase 2 dose of BOS172722 in combination with paclitaxel in those participants.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Advanced Nonhaematologic Malignancies
  • Neoplasms
Clinical Trial Details
NCT number NCT03328494
Study type Interventional
Source Boston Pharmaceuticals
Contact
Status Completed
Phase Phase 1
Start date October 13, 2017
Completion date March 16, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT03780517 - Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors Phase 1